The influence of pharmaceutical compounds on male fertility.
1. Steroid hormones can affect spermatogenesis and thereby fertility directly and/or indirectly. All antigonadotropically active steroids inhibit spermatogenesis via inhibition of gonadotropin secretion, mainly that of H. Androgens and steroids occurring in the biosynthetic chain of testosterone synthesis have a direct promoting effect on spermatogenesis if applied in high doses. It has not been possible as yet to make clinical use of this positive effect since it is obviously not possible to achieve the necessary intratesticular androgen concentrations. 2. As concerns the different androgens and the steroids in the androgen biosynthetic chain, and also all synthetic anabolics, there is no parallelism between the direct spermatogenic activity, the androgenic activity and the antigonadotropic activity. 3. Estrogens and synthetic gestagens do not inhibit spermatogenesis directly at the testicular level. All effects of estrogens can be abolished experimentally by adequate substitution with gonadotropins or androgens, or a combination of androgens and gonadotropins. 4. Only those antiandrogens inhibit spermatogenesis with additional antigonadotropic properties (e.g. cyproterone acetate). Pure antiandrogens, like flutamide or cyproterone, have a slight and transient influence on spermatogenesis at the most. If at all, they merely cause transient subfertility. 5. Beside steroids and several centrally active pharmaceutics (e.g. psychotropic drugs and several antihypertensive compounds), only siloxanes and methallibur seem to affect spermatogenesis via inhibition of gonadotropin secretion. Other antispermatogenic agents act by inhibition of mitosis (Colchicine, alkylating agents) or presumably via damage of the Sertoli cells. 6. Based on present knowledge, contraception in men could be principally managed by administration of a) androgens alone, b) gestagen/androgen combinations, c) estrogen/androgen combinations, d) certain antiandrogens. 7. The difficulties of contraception in men by steroid hormones or steroid hormone combinations have been pointed out. As regards the usefulness of antiandrogens for contraception, no definite conclusions can be drawn at the moment. All non-steroidal inhibitors of spermatogenesis which have been found up to the present are not suitable because of toxic effects.
D000726:Androgen Antagonists; D000728:Androgens / Q000494:pharmacology*; D000818:Animals; D003272:Contraceptive Agents, Male / Q000494:pharmacology; D003534:Cyproterone / Q000494:pharmacology; D004285:Dogs; D004967:Estrogens / Q000494:pharmacology*; D005298:Fertility / Q000187:drug effects*; D005640:Follicle Stimulating Hormone / Q000378:metabolism; D006065:Gonadotropins, Pituitary / Q000378:metabolism; D006801:Humans; D008297:Male; D009644:Norgestrel / Q000494:pharmacology; D009929:Organ Size / Q000187:drug effects; D011372:Progestins / Q000494:pharmacology*; D011485:Protein Binding / Q000187:drug effects; D051381:Rats; D012636:Secretory Rate / Q000187:drug effects; D013091:Spermatogenesis / Q000187:drug effects; D013737:Testis / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D013739:Testosterone / Q000494:pharmacology
D000726:Androgen Antagonists; D000728:Androgens; D003272:Contraceptive Agents, Male; D004967:Estrogens; D006065:Gonadotropins, Pituitary; D011372:Progestins; D009644:Norgestrel; D013739:Testosterone; D005640:Follicle Stimulating Hormone; D003534:Cyproterone